Skip to main content

Table 1 Effect of cisplatin (CP) and different treatments of AHE on lipid profile

From: Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Group

Total cholesterol (mg/dl)

HDL (mg/dl)

LDL (mg/dl)

Triglycerides (mg/dl)

Control

76.50 ± 0.29 b

25.17 ± 0.44b

48.62 ± 0.23b

70.50 ± 1.04b

CP

95.63 ± 0.32 a

20.30 ± 0.36a

165.4 ± 0.32a

92.83 ± 0.60a

AHE alone

76.13 ± 0.19 b

25.33 ± 0.33b

48.57 ± 0.20b

70.33 ± 0.67b

CP + AHE

90.33 ± 0.33 a, b, d

20.83 ± 0.44a, d**

144.0 ± 0.58a, b

84.67 ± 0.67a, b, d

AHE + CP

79.83 ± 0.44 a, b, c

24.03 ± 0.15b, c**

59.67 ± 0.33a, b

76.30 ± 0.35a, b, c

CP + Sily

78.67 ± 0.33 a**, b

24.17 ± 0.61b

58.43 ± 0.22a, b

73.50 ± 0.50b

  1. Values expressed as mean ± SEM
  2. a Significance at p < 0.0001 Vs. control group
  3. b Significance at p < 0.0001 Vs. Cisplatin (CP) group
  4. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
  5. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
  6. ** Significant difference p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests). Sily; Silymarin